Ferring Pharmaceuticals acquires two phase III ready orthobiologic product candidates from BioSET
Orthopaedics has grown to become one of five key therapeutic areas for Ferring since the 2005 launch of EUFLEXXA® (1% sodium hyaluronate) for the treatment for knee pain due to osteoarthritis.
“With the acquisition of the BioSET portfolio, Ferring intends to build on its growing success in orthopaedics,” said Michel Pettigrew, President of the Ferring Executive Board and COO, “By developing new orthobiologic products for joint fusion, we will expand and diversify our offering to include innovative solutions for orthopaedic surgery.”
Each year approximately two million procedures involving bone graft materials, including approximately 700,000 fusions, are performed in the U.S. alone. This number is increasing more than 5 percent annually[1] as orthopaedic surgeons treat an expanding, aging population of patients with severe bone degeneration and traumatic defects.
In addition to AMPLEX and PREFIX, Ferring has acquired a library of rationally designed biomimetic peptides intended for applications in bone and tissue repair.
About Ferring Pharmaceuticals:
Headquartered in Saint-Prex, Switzerland, Ferring Pharmaceuticals is a research-driven, specialty biopharmaceutical group active in global markets. The company identifies, develops and markets innovative products in the areas of reproductive health, urology, gastroenterology, endocrinology and orthopaedics. Ferring has its own operating subsidiaries in nearly 60 countries and markets its products in 110 countries. To learn more about Ferring or its products please visit www.ferring.com.
All trademarks mentioned are property of Ferring.
References
[1] 2014 BioMEDGPS
Website: http://www.ferring.com
Contact
Ferring Pharmaceuticals
Helen Gallagher
+41 (0) 58 301 00 51
helen.gallagher@ferring.com
Patrick Gorman
+41 (0) 58 301 00 53
patrick.gorman@ferring.com
This news is a press release provided by Ferring Pharmaceuticals.
-
4월 22일 10:20
-
4월 9일 15:28